Nexstim
5.1
EUR
+0.79 %
NXTMH
First North Finland
Medical Equipment & Services
Health Care
5,241 following
+0.79%
-2.67%
-15%
+63.99%
+77.08%
+73.47%
+100.79%
-3.41%
+119.22%
-99.16%
www.nexstim.com/investors/company-profile
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
P/E (adj.) (24e)
-382.93
EV/EBIT (adj.) (24e)
12,192.39
P/B (24e)
13.6
Dividend yield-% (24e)
-
Target price
4.00 EUR
Recommendation
Sell
Updated
20.10.2024
First North Finland
NXTMH
Daily low / high price
5 / 5.3
EUR
Market cap
34.5M EUR
Turnover
8.33K EUR
Volume
1.6K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Siltanen
Analyst
Latest videos
Financial calendar
Annual report
27.02.2025
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.1 | 6.4 | 9.5 | 7.2 | 9.1 | 11.9 | 14.1 | 15.2 |
| growth-% | 22.9 % | 55.5 % | 48.9 % | -23.9 % | 25.9 % | 29.9 % | 19.1 % | 7.4 % |
| EBITDA | -3.0 | -1.0 | 1.3 | -0.5 | 0.8 | 1.6 | 2.4 | 2.9 |
| EBIT (adj.) | -3.3 | -1.5 | 0.8 | -1.2 | 0.0 | 1.0 | 1.9 | 2.3 |
| EBIT | -3.3 | -1.5 | 0.8 | -1.2 | 0.0 | 1.0 | 1.9 | 2.3 |
| Profit before taxes | -4.1 | -0.7 | 1.3 | -1.3 | -0.1 | 0.9 | 1.7 | 2.2 |
| Net income | -4.1 | -0.8 | 1.3 | -1.3 | -0.1 | 0.9 | 1.7 | 2.2 |
| EPS (adj.) | -0.01 | -0.11 | 0.18 | -0.18 | -0.01 | 0.12 | 0.24 | 0.30 |
| growth-% | -201.5 % | 98.1 % | 26.3 % | |||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.15 |
| Dividend ratio | 25.0 % | 50.0 % |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -72.1 % | -15.8 % | 13.8 % | -7.3 % | 8.9 % | 13.7 % | 17.0 % | 18.9 % |
| EBIT-% (adj.) | -81.0 % | -22.7 % | 8.8 % | -16.9 % | 0.0 % | 8.2 % | 13.1 % | 15.1 % |
| EBIT-% | -81.0 % | -22.7 % | 8.8 % | -16.9 % | 0.0 % | 8.2 % | 13.1 % | 15.1 % |
| ROE | 373.1 % | -96.0 % | 36.0 % | -38.5 % | -3.5 % | 27.6 % | 38.8 % | 35.2 % |
| ROI | -73.1 % | -27.2 % | 11.4 % | -16.6 % | 0.0 % | 14.5 % | 26.6 % | 27.8 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 0.10 | 4.78 | 4.00 | 2.69 | 5.10 | 5.10 | 5.10 | 5.10 |
| Shares | 439.6 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 |
| Market cap | 43.1 | 34.8 | 29.1 | 19.6 | 37.1 | 37.1 | 37.1 | 37.1 |
| Enterprise value | 44.7 | 33.5 | 28.1 | 22.5 | 38.5 | 36.9 | 34.7 | 33.8 |
| EV/S | 10.9 | 5.2 | 3.0 | 3.1 | 4.2 | 3.1 | 2.5 | 2.2 |
| EV/EBITDA | - | - | 21.4 | - | 47.4 | 22.8 | 14.5 | 11.8 |
| EV/EBIT (adj.) | - | - | 33.6 | - | 12,191.2 | 37.9 | 18.7 | 14.8 |
| EV/EBIT | - | - | 33.6 | - | 12,191.2 | 37.9 | 18.7 | 14.8 |
| P/E (adj.) | - | - | 22.2 | - | - | 42.5 | 21.4 | 17.0 |
| P/E | - | - | 22.2 | - | - | 42.5 | 21.4 | 17.0 |
| P/B | - | 10.9 | 7.1 | 6.9 | 13.6 | 10.3 | 7.0 | 5.2 |
| P/S | 10.5 | 5.4 | 3.1 | 2.7 | 4.1 | 3.1 | 2.6 | 2.4 |
| Dividend yield | 1.2 % | 2.9 % | ||||||
| Equity ratio | -23.5 % | 31.9 % | 39.8 % | 28.6 % | 25.7 % | 31.2 % | 40.5 % | 48.7 % |
| Gearing ratio | -108.1 % | -40.6 % | -23.4 % | 105.6 % | 50.1 % | -5.2 % | -45.0 % | -45.9 % |
Quarter data
| Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5 | 4.7 | 7.2 | 3.2 | 5.9 | ||||
| EBITDA | -1.1 | 0.6 | -0.5 | -0.5 | 1.3 | ||||
| EBIT | -1.4 | 0.2 | -1.2 | -0.9 | 0.9 | ||||
| Profit before taxes | -1.4 | 0.1 | -1.3 | -0.9 | 0.8 | ||||
| Net income | -1.4 | 0.1 | -1.3 | -0.9 | 0.8 |
ShowingAll content types
Nexstim Receives System Order from University Hospital in United States
New Finnish Customer Orders Two Nexstim NBS 6 Systems
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Business news update from Nexstim
Nexstim Plc Business Update Q3 2024
Nexstim: Taking a breather after handsome returns
Nexstim Gains Import License for NBS System 5 in India
Nexstim Receives NBS 5 System Order from Californian Clinic
Nexstim expands its network of partner clinics
Nexstim Makes a Strategic Investment into a Management Services Organization of a Psychiatric Clinic in North Carolina, US
Nexstim Plc supports 13th International Symposium on nTMS in Neurosurgery and Neuromodulation and showcases NBS 6 system for presurgical mapping
Nexstim Receives NBS System 5 Order from European Customer
Nexstim Receives Order for NBS System 5 in Finland
New European Customer Orders Nexstim NBS System 5
Nexstim Q2'24: Potential attracts again
NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)
